Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease
Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaNot yet recruiting - verified February 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2016 Category: Research Source Type: clinical trials

Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease
Condition:   Breast NeoplasmsInterventions:   Drug: PD-0332991 (Palbociclib);   Drug: Fulvestrant;   Drug: PlaceboSponsors:   Spanish Breast Cancer Research Group;   AstraZenecaRecruiting - verified March 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2016 Category: Research Source Type: clinical trials

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Condition:   Prostatic NeoplasmsInterventions:   Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: Estramustine;   Drug: DegarelixSponsor:   The University of Texas Health Science Center, HoustonNot yet recruiting - verified September 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 17, 2015 Category: Research Source Type: clinical trials

Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy
Conditions:   Weak; Pelvic Floor;   Weak; Muscle;   Urinary IncontinenceIntervention:   Behavioral: pelvic floor muscle trainingSponsor:   University of Sao PauloNot yet recruiting - verified September 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2015 Category: Research Source Type: clinical trials

Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)
Conditions:   Hormonal Therapy;   Breast CancerIntervention:   Other: Body composition measurementSponsor:   Centre Jean PerrinRecruiting - verified July 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2015 Category: Research Source Type: clinical trials